
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
Pharmaceutical Technology Europe
Click the title above to open the Pharmaceutical Technology Europe September 2012 issue in an interactive PDF format.
about 14 years ago
The Macro Viewabout 14 years ago
Strategies for High Containmentabout 14 years ago
European Commission Investigates Pay-to-Delay Dealsabout 14 years ago
Regulatory Intervention in Paediatric Medicinesabout 14 years ago
Pre-use Filter-Integrity Testing: To Test or Not To Test?about 14 years ago
Tackling Tablet Stickingabout 14 years ago
News




